 Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
Rapamune- Rapamune
- Wyeth Brand of Sirolimus
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 0 | 4 | | 2003 | 4 | 0 | 4 | | 2004 | 3 | 2 | 5 | | 2005 | 4 | 3 | 7 | | 2006 | 5 | 0 | 5 | | 2007 | 2 | 1 | 3 | | 2008 | 1 | 3 | 4 | | 2009 | 2 | 2 | 4 | | 2010 | 8 | 3 | 11 | | 2011 | 6 | 3 | 9 | | 2012 | 7 | 5 | 12 | | 2013 | 7 | 3 | 10 | | 2014 | 7 | 3 | 10 | | 2015 | 0 | 1 | 1 | | 2016 | 2 | 1 | 3 | | 2017 | 0 | 3 | 3 | | 2018 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Waise TMZ, Rasti M, Duca FA, Zhang SY, Bauer PV, Rhodes CJ, Lam TKT. Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production. Nat Commun. 2019 02 12; 10(1):714.
-
Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
-
Ahmadiantehrani S, Gores EO, London SE. A complex mTOR response in habituation paradigms for a social signal in adult songbirds. Learn Mem. 2018 06; 25(6):273-282.
-
Ahmadiantehrani S, London SE. Bidirectional manipulation of mTOR signaling disrupts socially mediated vocal learning in juvenile songbirds. Proc Natl Acad Sci U S A. 2017 08 29; 114(35):9463-9468.
-
Blandino-Rosano M, Barbaresso R, Jimenez-Palomares M, Bozadjieva N, Werneck-de-Castro JP, Hatanaka M, Mirmira RG, Sonenberg N, Liu M, Rüegg MA, Hall MN, Bernal-Mizrachi E. Loss of mTORC1 signalling impairs ß-cell homeostasis and insulin processing. Nat Commun. 2017 07 12; 8:16014.
-
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 07; 18(7):946-957.
-
Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52.
-
Yue M, Pacheco G, Cheng T, Li J, Wang Y, Henske EP, Schuger L. Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis. Am J Pathol. 2016 07; 186(7):1825-1836.
-
Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.
-
Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|